Research News and Highlights

Explore news, updates and cutting-edge research related to real-world data and ALZ-NET.

Network news

Alzheimer’s Association Workgroup Publishes Biology-Based Criteria for Diagnosis and Staging of Alzheimer’s Disease

A workgroup convened by the Alzheimer’s Association has published revised criteria for the diagnosis and staging of Alzheimer’s disease based on the biology of the disease and reflecting recent advancements in Alzheimer’s research, diagnostics and treatment. The revised criteria define Alzheimer’s disease as a biological process that begins with the appearance of Alzheimer’s-related changes that happen in the brain before people exhibit memory and thinking problems. The 2024 update includes an updated biomarker classification system that includes blood-based biomarkers and a revised disease staging system.

Date Published: June 27, 2024
Publication: Alzheimer’s Association

FDA approves treatment for adults with Alzheimer’s disease

On July 2, 2024, the U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab), an amyloid beta-targeting antibody, for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials.

Date Published: July 2, 2024
Publication: FDA

Alzheimer’s Association Launches ALZ-NET: A Long-Term Data Collection and Sharing Network for New Treatments

The Alzheimer’s Association announces that the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) – a new platform that will collect long-term clinical and safety data from patients treated with FDA-approved Alzheimer’s disease therapies in real-world clinical settings – is launched and live.

Date published: August 1, 2022
Publication: Alzheimer’s Association

More ALZ-NET news and highlights

Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (AD), January 31, 2024

Radiology Takes on Alzheimer's Disease, October 4, 2023

Isaac Health joins ALZ-NET as a participating telehealth site, September 6, 2023

FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval (lecanemab), July 6, 2023

FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease (brexpiprazole), May 11, 2023

Emerging Therapies for Early Alzheimer’s Disease, April 3, 2023

Experts reframe ‘clinical meaningfulness’ in Alzheimer’s, February 7, 2023

FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment (lecanemab), January 6, 2023

Alzheimer’s Association Launches ALZ-NET Registry for Study of New Treatments for Alzheimer's Disease in Real-World Setting, August 2, 2022

Working Towards a World Without Alzheimer’s and All Other Dementia, November 26, 2021

Alzheimer’s Association announces national data registry for quick, transparent data sharing, November 12, 2021

National Alzheimer Disease Registry Announced to Collect Clinical Practice Data, November 12, 2021

Publications from ALZ-NET

ALZ-NET: Using Real World Evidence to Inform the Future of Alzheimer’s Treatment and Care
Published: December 2022

Alzheimer’s Association launches ALZ-NET: A long-term data collection and sharing network for new treatment
Published: September 2022

More news from the Alzheimer’s Association

The Alzheimer’s Association is dedicated to promoting awareness of the latest Alzheimer’s and dementia research, resources and news. Browse and share the articles, or sign up for our e-newsletter to stay informed on the global fight against Alzheimer’s and all other dementia.

Read More